Community Pharmacy Could Hold The Key To Saving The Lives Of 40,000 Men Every Year, UK New research from the Royal Pharmaceutical Society of Great Britain (RPSGB) could shed light on the reasons behind the poor state of men's
health in Britain. The RPSGB commissioned study, designed to discover how men's attitudes might affect their
healthcare, revealed that 59% of men are reluctant to ask for help and only seek medical advice if they are 'very ill or in great pain'.
Source: www.medicalnewstoday.comPortola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets In Clopidogrel (Plavix(R)) Non-Responders Portola Pharmaceuticals, a biopharmaceutical company developing innovative
drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, announced new clinical data that demonstrate PRT060128, the Company's novel anti-platelet drug that directly and reversibly inhibits the P2Y12 ADP receptor, overcomes high platelet reactivity (HPR) in patients who do not respond to clopidogrel (Plavix(R)).
Source: www.medicalnewstoday.comMerck Serono Launches Expansion Of Flagship Biotech Center To Meet Growing Patient Needs Merck Serono, the division for innovative pharmaceuticals of Merck KGaA, Darmstadt, Germany, today held a cornerstone ceremony at the Merck Serono Biotech Center (MSBC), its production site in Corsier-sur-Vevey, Switzerland, to mark the expansion of the site.
Source: www.medicalnewstoday.comUS FDA Approves 30-Minute Onset Of Action For Focalin(R) XR, Bringing Potential Benefits To ADHD Patients During Early Morning Period The US Food and Drug Administration (FDA) has approved a 30-minute onset of action for Focalin(R) XR (dexmethylphenidate HCl) extended-release capsules for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), bringing potential benefits for young patients and their families during the important morning period when they are preparing for school.
Source: www.medicalnewstoday.comViroPharma Announces Presentation Of Cinryze(TM) Data In Acute Treatment Of Hereditary Angioedema ViroPharma Incorporated (Nasdaq: VPHM) announced the presentation of data from its ongoing, open-label study, showing that in this study Cinryze(TM) C1 inhibitor therapy successfully treated all types of acute hereditary angioedema (HAE) attacks seen in the study through the date of analysis. Patients suffering acute attacks of HAE who were treated with Cinryze experienced improvement in symptoms at a median time of 30 minutes post treatment.
Source: www.medicalnewstoday.comNovexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial In Hospital Patients With Complicated Urinary Tract Infections Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced injectable antibacterial, which combines Novexel's broad spectrum beta-lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered Phase II clinical trials.
Source: www.medicalnewstoday.comMetabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982 Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new
medicines for the treatment of metabolic diseases, announced positive results from a Phase 1a clinical trial of MBX-2982. A summary of the results was presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) on November 1, 2008.
Source: www.medicalnewstoday.com
# posted by Network @ 3:00 PM
